Cytokines in Liver Injury and Repair

Preface. <strong>Section I: Cytokine-Induced Cell Death.</strong> <strong>1.</strong> Endogenous modulators of receptor-mediated hepatic cell death; H. Hentze, et al. <strong>2.</strong> Modulation of CD 95 (APO-1/Fas) induced hepatocyte death by NO; PR. Galle, et al. <strong>3.</strong> TGF-beta-induced liver cell apoptosis; R. Schulte-Hermann, et al. <strong>Section II: Regulation of Normal and Malignant</strong> <strong>Cell Growth by Cytokines.</strong> <strong>4.</strong> Proliferative and apoptotic effects of tumour necrosis factor in the liver and cells in culture; N. Fausto, J. Campbell. <strong>5.</strong> The role of insulin-like growth factor-II in hepatocarcinogenesis; P. Lund, et al. <strong>6.</strong> Transforming growth factor-beta and cancer; M. Reiss. <strong>7.</strong> Cytokines and hepatitis C virus replication; D. Moradpour, et al. <strong>Section III: Cytokine Signals in</strong> <strong>Fibrogenesis.</strong> <strong>8.</strong> Role of DDR2 receptor in the activation of hepatic stellate cells; E. Olaso, et al. <strong>9.</strong> PDGF signalling in activated stellate cells; M. Pinzani. <strong>10.</strong> Escape of activated hepatic stellate cells from TGF-beta control; S. Dooley, et al. <strong>11.</strong> Chemokines in the modulation of liver inflammation; F. Marra, et al. <strong>Section IV:</strong> <strong>Modulation of Fibrogenic Cytokine Response.</strong> <strong>12.</strong> Identification of fibrogenic genes in a polygenic mouse model of liver fibrosis; F. Lammert, et al. <strong>13.</strong> Cytokine transgenic models of fibrogenesis; S. Kanzler. <strong>14.</strong> The fibrogenic mediators of TGF-beta and TNF-alpha as surviving factors for activated hepatic stellate cells; G. Ramadori, B. Saile. <strong>15.</strong> Resolution of fibrosis by apoptosis of myofibroblasts; F. Murphy, J.P. Iredale. <strong>Section V: Cytokines in the Cause and</strong> <strong>Consequence of Cholestatis.</strong> <strong>16.</strong> Regulation of hepatic organic anion transporters by cytokines; A. Geier, et al. <strong>17.</strong> Reaction of cholangiocytes to inflammatory injury; C. Spirl&igrave;, et al. <strong>18.</strong> Bid antisense oligodeoxynucleotides as therapy for cholestatic liver injury; H. Higuchi, G.J. Gores. <strong>Section VI: Polymorphisms of Cytokines</strong> <strong>and Signalling.</strong> <strong>19.</strong> Regulation of interleukin-6-type cytokine signaling; P.C. Heinrich, et al. <strong>20.</strong> IL6-dependent signal transduction and its relevance in animal models; K.L. Streetz, et al. <strong>21.</strong> Predictive value of cytokine polymorphisms for liver disease; P.T. Donaldson, C.P. Day. </strong>Section VII: Therapeutic Cytokines and Modulators.</strong> <strong>22.</strong> PPAR&gamma; and fibrogenesis; T. Miyahara, et al. <strong>23.</strong> Cytokine modulation in the therapy of hepatic immunopathology and fibrosis; S.M. Wahl, et al. <strong>24.</strong> Matrix binding motifs and peptide mimetics as modulators of wound healing and fibrogenesis; D. Schuppan, et al. <strong>25.</strong> Endothelin and liver injury &endash; therapeutic antagonism of the endothelin system; D.C. Rockey. <strong>26.</strong> Transforming growth factor &beta; in the treatment of autoimmune disease; A.W. Lohse. <strong>Section</strong> <strong>VIII: Cytokine-Assisted Gene Therapies.</strong> <strong>27.</strong> The feasibility of antifibrotic gene therapy; T.J. Davern, D.M. Bissell. <strong>28.</strong> Experimental approaches to antifibrotic strategies using gene transfer; R. Weiskirchen, et al. <strong>29. Cytokine-assisted gene therapy: Anti-TGF-&beta; intervention using mutated forms of TGF-&beta; receptor; H. Ueno, et al. <strong>30.</strong> Cytokine-based gene therapy of hepatocellular carcinoma (HCC); C. Qian, et al. Index.